Results 221 to 230 of about 36,119 (263)

Genomic analysis unlocks the potential of denosumab as a targeted therapy for Crohn's disease. [PDF]

Sci Rep
Pranata R, Ratnasari N, Bayupurnama P, Indrarti F, Aulia N, Rahmawati H, Adikusuma W, Mugiyanto E, Irham LM, Gunarto C, Alya SS, Hadi VF, Sentosa GC, Wahyuningsih AT, Lin CF, Satria RD.   +15 more
europepmc   +1 more source

Treatment with denosumab reduces second hip fracture risk in elderly patients with osteoporotic femoral neck fractures. [PDF]

BMC Musculoskelet Disord
Wang Y, Pan K, Li X, Lv Q, Shao Y, Cao L.   +5 more
europepmc   +1 more source

Significant Response to Denosumab Yet with Severe Rebound Hypercalcemia in a 9-Year-Old Boy with Aneurysmal Bone Cyst: A Case Report. [PDF]

Children (Basel)
Allain L, Elbaz S, Sathyakumar S, Le Gallou W, Coleman C, Coltin H, Eugène D, Gupta A, Lava SAG, Renzi S.   +9 more
europepmc   +1 more source

Sequential treatment from bisphosphonate to denosumab improves lumbar spine bone mineral density in postmenopausal osteoporosis patients: A meta-analysis of randomized controlled trials

Jiang Xu, Siyi Hou, Xiaolei Deng, Liyou Hu, Jian Wang, Decai Hou   +5 more
openalex   +1 more source

Kritik boyutlu kemik defektlerinde denosumab ve ozon uygulamasının kemik iyileşmesi üzerine etkisinin araştırılması

Ersin Keskin, Beyza Kaya, Ayfer Aktaş
openalex   +1 more source

Destructieve artropathie bij een oudere dame

, 2018
Anisau, Aliaksandr, Desimpel, Julie, Vanhoenacker, Filip   +2 more
core  

Some of the next articles are maybe not open access.

Related searches:

Denosumab Discontinuation

Current Osteoporosis Reports, 2022
To review the pathophysiology, the clinical consequences as well as way of mitigating the effects of denosumab discontinuation.Treatment with denosumab (DMAB) is reversible and upon discontinuation there is a rapid increase in bone turnover and a subsequent bone loss.
Anne Sophie Sølling, Elena Tsourdi, Torben Harsløf, Bente L Langdahl   +3 more
openaire   +2 more sources